Last reviewed · How we verify
Erenumab 140 mg
Erenumab 140 mg is a Small molecule drug developed by Amgen. It is currently FDA-approved. Also known as: Aimovig.
At a glance
| Generic name | Erenumab 140 mg |
|---|---|
| Also known as | Aimovig |
| Sponsor | Amgen |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Multidisciplinary Translational Approach to Investigate Mechanisms Predictors & Prevention of Persistent PTH (PHASE2)
- A Study to Evaluate the Efficacy and Safety of Erenumab in Adults With Medication Overuse Headache (PHASE4)
- Safety and Efficacy of Erenumab-aooe in Patients With Temporomandibular Disorder (PHASE2)
- Assessment of Prolonged Safety and tOLerability of in Migraine Patients in a Long-term OpeN-label Study (PHASE4)
- Erenumab - Comprehensive Assessment of Efficacy in (High-Frequency) Episodic Migraine (PHASE4)
- Biomarker and Genetic Predictors of Erenumab Treatment Response (PHASE4)
- Erenumab-aooe for the Management of Trigeminal Neuropathic Pain. (PHASE2)
- Treatment of Acute PTH With a CGRP Receptor mAb in Military Service Members and Civilians With mTBI (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Erenumab 140 mg CI brief — competitive landscape report
- Erenumab 140 mg updates RSS · CI watch RSS
- Amgen portfolio CI
Frequently asked questions about Erenumab 140 mg
What is Erenumab 140 mg?
Erenumab 140 mg is a Small molecule drug developed by Amgen.
Who makes Erenumab 140 mg?
Erenumab 140 mg is developed and marketed by Amgen (see full Amgen pipeline at /company/amgen).
Is Erenumab 140 mg also known as anything else?
Erenumab 140 mg is also known as Aimovig.
What development phase is Erenumab 140 mg in?
Erenumab 140 mg is FDA-approved (marketed).
Related
- Manufacturer: Amgen — full pipeline
- Also known as: Aimovig
- Compare: Erenumab 140 mg vs similar drugs
- Pricing: Erenumab 140 mg cost, discount & access